NMPA Approves Marketing Update for Baiyunshan's Drug Products
China’s NMPA approves marketing update for Baiyunshan's Pseudoephedrine Granules and Paracetamol.
The National Medical Products Administration has approved a
supplementary medication application for Guangxi Baiyunshan Yingkang
Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Baiyunshan Pharmaceutical
Holdings Company. The permission relates to a modification in the topic of the
drug marketing authorisation for their product, Pseudoephedrine Granules and
Compound Paracetamol. The company's product portfolio is taking a significant
stride forward with this regulatory milestone.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP
Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral
Discussion